Milwaukee, WINCT05794880Now EnrollingIRB Ready

Leukemia Clinical Trial in Milwaukee, WI

Access cutting-edge leukemia treatment through this clinical trial at a research site in Milwaukee. Study-provided care at no cost to qualified participants.

Sponsored by Medical College of Wisconsin

Quick Self-Assessment

See if you qualify for this Milwaukee location

Preparing your pre-screening questions…

Expert Care in Milwaukee

Access leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related leukemia treatment provided free

Apply for This Milwaukee Location

Check if you qualify for this leukemia clinical trial in Milwaukee, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Milwaukee

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Milwaukee site if eligible
  4. 4Begin participation

About This Leukemia Study in Milwaukee

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Sponsor: Medical College of Wisconsin

Who Can Participate

Inclusion Criteria

Patient age \< 25 years. Both genders and all races eligible.
Disease eligibility
Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%)
Myelodysplasia
Acute lymphoblastic leukemia - Disease status: MRD negative
Chronic myelogenous leukemia - Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase
Mixed lineage or biphenotypic acute leukemia- Disease status: MRD negative
Lymphoblastic lymphoma - Disease status: in remission
Burkitt's lymphoma/leukemia - Disease status: in remission
Lymphoma after relapse - Disease status: in remission
Other malignant hematologic diseases in remission (to be approved by PI)
Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play Score ≥ 60 for patients under 16 years of age (Appendix 1)
Evaluation of organ status as per MCW BMT SOP
Infectious disease criteria: No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic.
Signed consent by parent/guardian or able to give consent if ≥18 years.
Negative pregnancy test for patients capable of childbearing potential
Sexually active patients capable of child-bearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment. Sexually active men must agree to use barrier contraceptive for the duration of treatment. Donor Eligibility:
Unrelated donor meets National Marrow Donor Program criteria for donation
Infectious disease testing
MCW BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.
Only Peripheral blood stem cells will be used for stem cell source on this study therefore donor must be willing to undergo G-CSF mobilization and stem cell apheresis. Donor matching. High resolution typing at all loci to be performed.
Unrelated Donor: a. HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or 10/10 alleles (HLA A, B, C, DRB1, DQB1).Donor and collection center willing to undergo mobilization and apheresis
Haploidentical Related Donor:
Haploidentical parent or other related donor: Minimum match level full haploidentical (at least 5/10; HLA A, B, C, DRB1, DQB1 alleles), but use of haploidentical donors with extra matches (e.g. 6, 7, or 8/10) encouraged.

Exclusion Criteria

Patients who do not meet disease, organ, or infectious criteria.
No suitable donor
Pregnant or lactating patients are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants
Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol. Maintenance or other post-HCT therapy can be considered after discussion with the study PI.
Participating in a concomitant Phase 1 or 2 study involving treatment of disease
Active malignancy other than eligible disease specified in the protocol. Patients with prior malignancy can be eligible as long as at least 1 year post treatment for that malignancy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milwaukee?

Yes, this clinical trial (NCT05794880) has an active research site in Milwaukee, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Leukemia Treatment Options in Milwaukee, WI

If you're searching for leukemia treatment options in Milwaukee, WI, this clinical trial (NCT05794880) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milwaukee research site is actively enrolling participants for this clinical trial. You'll receive care from experienced leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Milwaukee, WI

See all leukemia clinical trials recruiting in Milwaukee — not just this study.

Browse Leukemia Trials in Milwaukee →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsChronic Lymphocytic Leukemia TrialsAcute Myeloid Leukemia TrialsMyelodysplastic Syndromes TrialsHeart Attack TrialsPediatric Cancer TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Milwaukee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Milwaukee, WI